To read the full story, subscribe or sign in.

RedX Pharma Raising $17M for Antiviral, Antibody Work

July 18, 2012

LONDON – RedX Pharma Ltd. is planning a £10.8 million (US$16.8 million) investment to extend the reach of its expertise in the structural modification of marketed drugs into antibiotics and antivirals.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...